Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 30HR+/HER2- Advanced Breast Cancer 3Breast Cancer Metastatic 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Esophageal Squamous Cell Carcinoma 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Solid Tumor 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-positive Breast Cancer 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasm Female 1Breast Diseases 1Brain Neoplasms 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1

Interventions

dalpiciclib 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
HR+/HER2- Advanced Breast Cancer × dalpiciclib × Clear all
NCT06556862 2025-08-13

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Beijing 302 Hospital

Phase 2 Not yet recruiting
155 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

NCT06711094 2024-12-02

Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

Fujian Medical University

Phase NA Not yet recruiting
52 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

NCT05586841 2022-10-19

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Beijing 302 Hospital

Phase 1 Unknown
30 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡